Epidemiological and clinical data suggest soy derivatives could provide a promising treatment in the management of menopause-related symptoms in postmenopausal women.

Although conflicting results have been reported in literature, some clinical studies (2) confirm the health benefits of soy derivatives. These contradictory results can be partly explained by the high variability in chemical composition among the different soybean products tested.

Soyselect^® eliminates this source of bias, thanks to its highly standardized profile.

To obtain biological reproducible data in terms of safety and efficacy the active ingredients must be standardized, thus being the same over the time, stable and devoid of unpredictable toxicity and side effects.

Soyselect^® features a double standardization of the active components responsible for its efficacy and the exact ratio between the two classes of actives is responsible of its increased bioavailability:

ISOFLAVONES - 13-17% (genistin and daidzin) by HPLC

SAPONINS - not less than 18% (B-group) by HPLC